Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

RXi Pharmaceuticals Corp. is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition. RXi's first RNAi product candidate, RXI-109, is currently in clinical trials. It targets connective tissue growth factor, a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.